Immunic Names Industry Veteran Erik Lundgren as CEO Ahead of Phase 3 Readout
IMUX•Immunic appointed Erik Lundgren, former Genentech/Roche SVP with MS and Ocrevus launch expertise, as CEO effective June 1, 2026. He will steer vidofludimus calcium through pivotal phase 3 ENSURE RMS readout expected by year-end and prepare NDA filing, commercialization, and a planned PPMS phase 3 program.
1. Leadership Transition and CEO Background
Immunic appointed Erik Lundgren as CEO effective June 1, 2026, succeeding Daniel Vitt who shifts to scientific strategy. Lundgren brings nearly two decades of biopharma experience at Genentech and Roche, including leading the Ocrevus® launch and overseeing global commercial portfolios.
2. Clinical Development Focus and Milestones
Under Lundgren’s leadership, Immunic will advance vidofludimus calcium through the pivotal phase 3 ENSURE program in relapsing MS with top-line data expected by year-end, and launch a planned phase 3 trial in primary progressive MS ahead of potential NDA filing and regulatory approval.
3. NDA and Commercialization Preparation
The company is preparing for a new drug application for vidofludimus calcium in RMS and PPMS, building commercial infrastructure and strategic plans to support market launch upon regulatory clearance, positioning Immunic as a commercial-stage MS therapy provider.
4. Executive Equity Incentives
Lundgren received an inducement grant of options to purchase 1,000,000 shares under the 2026 Equity Compensation Plan, vesting 25% after one year and the remainder monthly over three years, aligning management incentives with long-term value creation.
